| Literature DB >> 18243661 |
Mariusz Z Ratajczak1, Ewa K Zuba-Surma, Marcin Wysoczynski, Wu Wan, Janina Ratajczak, Wojciech Wojakowski, Magda Kucia.
Abstract
Regenerative medicine and tissue engineering are searching for a novel stem cell based therapeutic strategy that will allow for efficient treatment or even potential replacement of damaged organs. The pluripotent stem cell (PSC), which gives rise to cells from all three germ lineages, seems to be the most ideal candidate for such therapies. PSC could be extracted from developing embryos. However, since this source of stem cells for potential therapeutic purposes remains controversial, stem cell researchers look for PSC that could be isolated from the adult tissues or generated from already differentiated cells. True PSC should possess both potential for multilineage differentiation in vitro and, more importantly, also be able to complement in vivo blastocyst development. This review will summarize current approaches and limitations to isolate PSC from adult tissues or, alternatively, to generate it by nuclear reprogramming from already differentiated somatic cells.Mesh:
Year: 2008 PMID: 18243661 PMCID: PMC2692479 DOI: 10.1016/j.jaut.2007.12.003
Source DB: PubMed Journal: J Autoimmun ISSN: 0896-8411 Impact factor: 7.094